ImmuPharma

IMM: 18.50 +0.75 (+4.23%) delayed: 11 Dec 2019, 17:30

Trade now

ImmuPharma Fundamentals

Share Price Information

Name ImmuPharma
Epic IMM
Sector Biotechnology
ISIN GB0033711010
Activites ImmuPharma PLC (formerly General Industries PLC) is developing innovative therapies for specialist diseases, It is headquartered in London and has its research operations in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). ImmuPharma is dedicated to the development of innovative drugs to treat serious medical conditions, characterised by: High unmet medical need; Low marketing costs; Relatively low development costs.. Founded first in Basel, Switzerland in 1999 and led by an experienced management team, ImmuPharma now has important R&D collaboration arrangements with highly respected health and medical research laboratories in Europe. The company plans either to bring its drug candidates to market itself, or to license them in corporate deals to other pharmaceutical companies.
Index n/a

Key numbers

Latest Share price (p) 18.50 Net gearing (%) -44.79
Market capitalisation (£m) 29.71 Gross gearing (%) 11.94
Shares in issue (m) 167.36 Debt ratio 0.29
P/E ratio -3.42 Debt-to-equity ratio 0.02
Total dividends per share (p) 0.00 Assets / equity ratio 1.14
Dividend yield (%) 0.00 Price to book value 3.90
Dividend cover 0.00 ROCE (%) -104.05
Earning per share (p) -5.19 EPS growth (%) -9.26
52-week high / low (p) 32.00 / 6.91 DPS growth (%) n/a

Results at a glance

Date Type Turnover (£m) Profit (£m) Basic EPS Currency
31 Dec 2018 Full Year 0 -7 -5.19 GBP
31 Dec 2017 Full Year 0 -6 -4.75 GBP
31 Dec 2016 Full Year 0 -5 -4.54 GBP

Dividend history

Period Ex-date Pay-date Net dividend Currency Total for year

Contact details

Company name Immupharma
Address 50 Broadway, Westminster, London SW1H 0RG.
Telephone +44 (0)20 7152 4080
Website http://www.immupharma.com/

Advisors

Company's broker Panmure Gordon & Co
Company's joint broker Noble & Company Limited
NOMAD Panmure Gordon & Co
Registrar Computershare Investor Service
Auditors Nexia Smith & Williamson
Solicitors Bircham Dyson Bell

Directors

Appointed Director Position
16 Feb 2006 Dimitri F Dimitriou Chief Executive Officer
16 Feb 2006 Dr Robert Henri Zimmer Chief Scientific Officer
30 Sep 2015 Timothy Paul McCarthy Non-Executive Chairman
07 Feb 2007 Dr Franco di Muzio Non-Executive Director
30 Apr 2015 Dr Stephane Robert George Mery Non-Executive Director

Company financials

Assets (£m) 2018 2017 2016
Reporting date 31 Dec 2018 31 Dec 2017 31 Dec 2016
Tangible assets 0 0 0
Intangible asssets and goodwill 0 0 1
Investments and other non-current assets 2 0 0
Total non-current assets 3 1 1
Inventory / work in progress 0 0 0
Trade and other receivables 0 1 3
Cash and equivalents 5 3 2
Other current assets and asset held for resale 1 1 2
Total of all assets 9 5 7
Liabilities (£m) 2018 2017 2016
Short term liabilities 1 1 1
Long term liabilities 0 0 0
Other liabilites / pension etc 0 0 0
Total of all liabilities 1 1 1
Net assets (£m) 2018 2017 2016
Net assets 8 4 6
Equity (£m) 2018 2017 2016
Share capital 14 13 12
Minority interests 0 0 0
Retained earnings -33 -26 -19
Share premium account 27 19 16
Other equity -1 -3 -3
Total equity 8 4 6
Cash Flow (£m) 2018 2017 2016
Cash from operating activities -5 -4 -6
Cashflow before financing -7 -4 -6
Increase / decrease in Cash 2 1 1
Income (£m) 2018 2017 2016
Turnover 0 0 0
Cost of sales 0 0 0
Gross profit 0 0 0
Operating profit -8 -7 -7
Pre-tax profit -8 -7 -6
Profit / loss for the year -7 -6 -5